Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
drugs
life sciences
national blog main
4
×
boston blog main
boston top stories
fda
patisiran
akcea therapeutics
alnylam pharmaceuticals
boston
inotersen
national top stories
new york blog main
new york top stories
onpattro
rna interference
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
tafamidis
acute hepatic porphyrias
akin akinc
aminolevulinic acid
anylam pharmaceuticals
barry greene
biotech
boston university
cannabidiol
cardiomyopathy
dan ollendorf
dravet syndrome
epidiolex
fen-phen
fenfluramine
givosiran
gw pharmaceuticals
hereditary transthyretin amyloidosis
john berk
What
ago
4
×
fda
4
×
alnylam
drug
medicine
approved
battle
patients
pharmaceuticals
rare
rna
sets
weeks
akcea
amyloidosis
approval
approve
attr
available
awaits
biological
cannabis
crossed
data
debilitating
decades
decision
derivative
discovered
disease
epilepsy
fingers
form
friday
genetic
gw
gw’s
historic
indicated
interference
Language
Current search:
" national blog main "
×
fda
×
ago
×
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com
5 years ago
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug